Kondelkova K, Krejsek J, Borska L, Fiala Z, Hamakova K, Andrys C
Department of Clinical Immunology and Allergology, Charles University in Prague, Faculty of Medicine and University Hospital Hradec Kralove, Czech Republic.
Allergol Immunopathol (Madr). 2013 May-Jun;41(3):158-62. doi: 10.1016/j.aller.2012.02.006. Epub 2012 Jul 4.
CD163 is the monocyte/macrophage receptor for haptoglobin-haemoglobin complexes. The aim of this study was to assess the kinetics in the expression of CD163 on monocytes and the concentration of soluble sCD163 in serum of psoriatic patients in order to examine the effect of Goeckerman therapy.
sCD163 was measured in 71 patients before and after therapy, and in 57 healthy donors. A subgroup of 40 patients and 25 controls was used to assess the expression of membrane CD163. sCD163 was evaluated by ELISA. Flow cytometry method was used to determine the expression of membrane CD163 on monocytes, expressed as mean fluorescence index (MFI).
Before therapy, the serum level of sCD163 was significantly higher in our patients than in controls (P=0.0154). However, we observed a profound decrease in sCD163 in our patients after therapy (P=0.0037). Similar to sCD163, pre-treatment expression of CD163 on monocytes was significantly more enhanced in patients than that in controls (P=0.0078). There was a trend towards down-regulation of the expression after therapy, nonetheless, the change was not statistically significant compared to the values before therapy (P=0.8666). This was also confirmed by comparison with controls which displayed lower expression of CD163 than patients after therapy (P=0.0019). The disease activity, expressed as PASI score, was significantly decreased in our patients by GT (P=0.0001).
While sCD163 level in psoriatic patients was diminished after GT therapy, CD163 expression on monocytes was altered only to a minor extent.
CD163是触珠蛋白-血红蛋白复合物的单核细胞/巨噬细胞受体。本研究旨在评估银屑病患者单核细胞上CD163的表达动力学以及血清中可溶性sCD163的浓度，以研究Goeckerman疗法的效果。
检测了71例患者治疗前后以及57例健康供者的sCD163。选取40例患者和25例对照组成的亚组来评估膜CD163的表达。采用ELISA法评估sCD163。运用流式细胞术方法测定单核细胞上膜CD163的表达，以平均荧光指数（MFI）表示。
治疗前，患者血清中的sCD163水平显著高于对照组（P = 0.0154）。然而，我们观察到治疗后患者血清中的sCD163显著降低（P = 0.0037）。与sCD163相似，患者单核细胞上CD163的治疗前表达显著高于对照组（P = 0.0078）。治疗后表达有下调趋势，尽管如此，与治疗前的值相比，变化无统计学意义（P = 0.8666）。与治疗后CD163表达低于患者的对照组相比，这一点也得到了证实（P = 0.0019）。以PASI评分表示的疾病活动度在我们的患者中经Goeckerman疗法后显著降低（P = 0.0001）。
虽然银屑病患者经Goeckerman疗法后sCD163水平降低，但单核细胞上CD163的表达仅略有改变。
